OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 18.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,892 shares of the company's stock after selling 4,901 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.10% of Praxis Precision Medicines worth $921,000 at the end of the most recent reporting period.A number of other institutional investors have also recently added to or reduced their stakes in PRAX. HighVista Strategies LLC boosted its stake in Praxis Precision Medicines by 71.3% during the second quarter. HighVista Strategies LLC now owns 67,288 shares of the company's stock worth $2,829,000 after buying an additional 28,002 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth $1,356,000. B Group Inc. raised its holdings in shares of Praxis Precision Medicines by 84.2% during the 2nd quarter. B Group Inc. now owns 35,000 shares of the company's stock worth $1,472,000 after acquiring an additional 16,000 shares during the period. Vivo Capital LLC acquired a new position in shares of Praxis Precision Medicines during the 2nd quarter valued at about $7,048,000. Finally, Maven Securities LTD purchased a new stake in shares of Praxis Precision Medicines in the second quarter valued at about $210,000. Hedge funds and other institutional investors own 67.84% of the company's stock. Insider Transactions at Praxis Precision MedicinesIn related news, General Counsel Alex Nemiroff sold 25,130 shares of the firm's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the transaction, the general counsel directly owned 20,832 shares in the company, valued at $4,022,450.88. This trade represents a 54.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lauren Mastrocola sold 13,600 shares of the business's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the sale, the insider owned 10,442 shares in the company, valued at $2,005,699.36. This trade represents a 56.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.70% of the company's stock. Analyst Upgrades and DowngradesA number of equities analysts have commented on the stock. Guggenheim reaffirmed a "buy" rating and set a $760.00 target price (up from $540.00) on shares of Praxis Precision Medicines in a research note on Tuesday. Truist Financial increased their price target on shares of Praxis Precision Medicines from $360.00 to $500.00 and gave the company a "buy" rating in a research note on Monday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Praxis Precision Medicines in a research report on Monday. HC Wainwright reiterated a "buy" rating and issued a $340.00 price objective (up from $258.00) on shares of Praxis Precision Medicines in a report on Friday, December 5th. Finally, Chardan Capital upgraded Praxis Precision Medicines to a "strong-buy" rating in a research report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $333.00.Read Our Latest Stock Report on Praxis Precision MedicinesPraxis Precision Medicines Stock Up 2.2%Shares of NASDAQ PRAX opened at $267.28 on Friday. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -20.72 and a beta of 2.95. Praxis Precision Medicines, Inc. has a 52-week low of $26.70 and a 52-week high of $278.44. The business's 50 day moving average is $167.50 and its two-hundred day moving average is $88.71. Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) EPS for the quarter, topping the consensus estimate of ($3.45) by $0.09. Analysts anticipate that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year. Praxis Precision Medicines Company Profile (Free Report)Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.Further ReadingFive stocks we like better than Praxis Precision MedicinesExpert Stock Trading Psychology Tips3 Recently Downgraded Stocks to Avoid in 2026Dividend Screener: How to Evaluate Dividend Stocks Before BuyingThe Chip Boom Is Back: 3 Stocks Positioned for Huge GainsInvesting in Construction StocksOracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 RallyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Praxis Precision Medicines Right Now?Before you consider Praxis Precision Medicines, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here